Jiangbo Pharmaceuticals' Hongrui Factory Receives GMP Certificate

LAIYANG, China, Jan. 4, 2011 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals, Inc. (Nasdaq: JGBO) ("Jiangbo" or the "Company"), a pharmaceutical company with its principal operations in the People's Republic of China, today announced that its  Hongrui factory has been awarded with the Good Manufacturing Practices Certificate for Pharmaceutical Products ("GMP Certificate") by China's State Food and Drug Administration ("SFDA"). The GMP Certificate is valid until the end of 2015. Based on the new GMP Certificate, the Company's Hongrui factory is allowed to manufacture traditional Chinese medicines ("TCMs") in the form of tablet, granule, pill, mixture, syrup, concentrated decoction, and oral intake solution. It is also allowed to produce lactulose concentrate, which is used as a raw material in various medicines.

The Company completed the renovation and upgrade of its Hongrui factory in October 2010. As a result, oral intake solution and lactulose concentrate were newly added to its GMP Certificate. The Company has also re-launched several of the traditional Chinese medicines produced at Honrui, including Laiyang Pear Cough Syrup and Kang Gu Sui Yan Pian (an osteomyelitis treatment tablet).

"We are pleased to have received the GMP Certificate, which has allowed us to re-launch several of the exciting TCMs we obtained in the Hongrui acquisition. We expect the TCMs produced at Hongrui to contribute meaningfully to Jiangbo's revenues and earnings during calendar year 2011," said Mr. Linxian Jin, the Company's Chief Executive Officer.

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals is engaged in the research, development, production, marketing and sales of pharmaceutical products in China. The Company's operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong Province. Jiangbo produces both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. For additional information, please visit the Company's website (www.jiangbopharma.com).

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers, product obsolescence, and risks to the Company's outlook for production at the Hongrui facility. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

SOURCE Jiangbo Pharmaceuticals, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED